Dienstag, 06. Dezember 2016


  • Pressemitteilung BoxID 60229

Acquisition of Dabur Pharma successfully closed

(lifePR) (Bad Homburg v.d.H, ) Fresenius Kabi has successfully closed the acquisition of Dabur Pharma Ltd. In April 2008, the company had announced the acquisition of 73.3 % of the share capital for a price of INR 76.50 per share in cash. Fresenius Kabi has now acquired a further 17.6 % shareholding for a price of INR 76.50 per share in cash through a public offer. Closing of the transaction had also been subject to relevant approvals required under Indian law, which have been received.

The acquisition significantly expands Fresenus Kabi's i.v. drug portfolio and secures its supply of high quality APIs for cytostatics. Dabur Pharma, headquartered in New Delhi, is one of the leading suppliers of generic drugs and active pharmaceutical ingredients (API) to treat cancer. The company holds a substantial number of drug registrations in Asia, Europe and the US.

Dabur Pharma had consolidated revenues of about € 47 million in fiscal year 2007/2008 (April 1, 2007 to March 31, 2008).

Dabur Pharma will be consolidated as from September 1, 2008 in the financial statements of Fresenius Group.

About Fresenius Kabi
Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume substitution and intravenously administered drugs as well as parenteral and enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With its philosophy "Caring for life" and a comprehensive product portfolio, the company aims at improving the quality of life of patients all over the world. In 2007, Fresenius Kabi achieved sales of € 2,030 million and an operating profit of € 332 million. On June 30, 2008 the company had 18,323 employees.Fresenius Kabi AG is a 100 % subsidiary of the health care group Fresenius SE.

About Dabur
Dabur Pharma Ltd. is committed to the discovery, development and marketing of drugs that fight cancer. Dedicated to its mission of making cancer therapy available to more and more people, it has been expanding ever since inception. The company is the leader in the Indian oncology market and it offers a complete range of products in this segment spanning across injectables, orals, intermediates and APIs and is present in over 40 countries. As of June 30, 2008, the company has 156,677,400 shares outstanding.

Fresenius AG (SE)

Fresenius is a health care group with international operations, providing products and services for dialysis, hospital and outpatient medical care. In 2007, group sales were approx. € 11.4 billion. On June 30, 2008 the Fresenius Group had 117,453 employees worldwide. For more information visit the Company's website at www.fresenius.com .

Diese Pressemitteilungen könnten Sie auch interessieren

EU-Tagung mit religiösen Führungspersönlichkeiten

, Medien & Kommunikation, Freikirche der Siebenten-Tags-Adventisten in Deutschland / Süddeutscher Verband KdöR

Die Religionsgemeinschaf­ten in Europa müssen sich für die gesellschaftliche Eingliederung von Migranten einsetzen, wissen aber, dass viele ihrer...

Forum Marketing der Metropolregion Nürnberg trifft sich bei hl-studios

, Medien & Kommunikation, hl-studios GmbH - Agentur für Industriekommunikation

Eine Region – viele Geschichten: Mit der Mitmachkampagne „Platz für…“ erzählen Menschen aus der Metropolregion Nürnberg ihre Geschichte. Denn...

Quantensprung für Home Video Entertainment-Systeme: Tele Columbus stellt mit advanceTV das Fernsehen der Zukunft vor

, Medien & Kommunikation, Tele Columbus Gruppe

. Multiscreen-fähige LiveTV- und VoD-Plattform mit einheitlicher, intuitiver Benutzeroberfläche Premium-EPG mit Inhaltesuche über sämtliche...

Disclaimer